KORU Medical Systems (KRMD) Piper Sandler 36th Annual Healthcare Conference summary

Strategic achievements and growth drivers

• Achieved double-digit growth and on track for cash flow positivity by Q4, with recent growth in the 15%-20% range.

• U.S. SCIG market rebounded, now growing 8%-10%, aided by a new go-to-market strategy and share gains.

• International (OUS) business grew over 30% year-to-date, driven by new partnerships and market entries.

• Novel therapies business expanded with three new collaboration deals, adding future pipeline opportunities.

• Improved gross margin profile and disciplined OpEx management support financial targets.

Market outlook and growth opportunities

• SCIG market is only 20% penetrated, offering significant headroom for expansion.

• Major pharmaceutical partners have invested in plasma production, supporting long-term market growth.

• External forecasts predict 7%-9% global SCIG market growth, with increasing adoption by healthcare systems.

• Over 1,000 drugs in the pipeline are moving to subcutaneous delivery, expected to drive further market penetration.

• Innovations in administration and new devices are anticipated to accelerate SCIG adoption.

Commercial strategy and execution

• International focus includes partnerships with electronic pump companies and pharmaceutical firms, entering new geographies.

• OUS market share increased by 3-4 points this year, with expectations to grow at least 20% annually.

• U.S. sales force refocused using analytics and AI to target underpenetrated areas, resulting in improved account performance.

• Key account negotiations in the U.S. have leveraged access to thousands of pharmacies.

• Major OUS deal in progress could significantly boost international growth.